A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

Sponsor

AstraZeneca (Industry)

Overall Status

Terminated

CT.gov ID

NCT01219543

Collaborator

(none)

Enrollment

Location

Arms

Duration (Months)

1.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is Phase I, open-label and dose escalation study to evaluate the safety and tolerability of AZD1480(JAK2 inhibitor) in Asian patients with advanced solid tumors (Part A and C) and in patients with advanced HCC (Part B) in the escalation phase, EGFR or ROS mutant NSCLC and non-smokers with lung metastasis and gastric cancer in the expansion phase and to evaluate daily and BID dosing.

Condition or Disease	Intervention/Treatment	Phase
Solid Tumour Advanced Solid Malignancies Child-Pugh A to B7 Advanced Hepatocellular Carcinoma EGFR and/or ROS Mutant NSCLC Lung Metastasis Carcinoma Gastric Cancer	Drug: AZD1480 Daily Drug: AZD1480 BID	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

47 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase I, Open-label, Multicentre, Dose Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 in Asian Patients With Advanced Solid Malignancies and Asian Patients With Child-Pugh A to B7 Advanced Hepatocellular Carcinoma (HCC) in the Escalation Phase, Estimated Glomerular Filtration Rate(EGFR) or ROS Mutant NSCLC and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour With Biopsy Available in the Expansion Phase.

Study Start Date :

Nov 1, 2010

Actual Primary Completion Date :

Dec 1, 2012

Actual Study Completion Date :

Dec 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Part A Daily dosing of AZD1480 to the patients with solid tumours excluding HCC	Drug: AZD1480 Daily Oral Dose, Capsule, Daily Dosing
Experimental: Part B BID dosing of AZD1480 to the patients with advanced HCC (Child-Pugh A to B7)	Drug: AZD1480 BID Oral Dose, Capsule, BID Dosing
Experimental: Part C BID dosing of AZD1480 to the patients with solid tumours excluding HCC	Drug: AZD1480 BID Oral Dose, Capsule, BID Dosing
Experimental: Expansion BID dosing of AZD1480 to the patients with EGFR or ROS mutant NSCLC and non-smokers with lung metastasis and gastric cancer and solid tumour with biopsy available.	Drug: AZD1480 BID Oral Dose, Capsule, BID Dosing

Outcome Measures

Primary Outcome Measures

To investigate the safety and tolerability of AZD1480 [Safety and tolerability monitoring will proceed for whole study period. Screening, Cycle1Day1, Cycle1Day5 (only for Part B), Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle2Day8 and Day1 of further Cycles, IP discontinued visit and 30-days follow up]

Secondary Outcome Measures

To evaluate the pharmacokinetics (PK) of AZD1480 following single dose and multiple doses [Part A and Expansion - 12 times during Cycle 1, 11 times during Cycle 2. Part B and C - 11 times during Cycle 1, 10 times during Cycle 2. *1 additional PK sample in Cycle 1 will be collect for optional biopsy sample collected patients.]
To obtain a preliminary assessment of the anti-tumour activity of AZD1480 [Tumour response assessment by RECIST (Response Evaluation Criteria In Solid Tumors) version 1.1 every 6 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male or female aged 18 years or older
For Part A and C: Histological or cytological confirmation of a solid malignant tumour refractory to standard therapies or for which no standard therapies exist. Patients with lymphoma & HCC are excluded.
For Expansion : Histological or cytological confirmation of
Expansion 1: EGFR and/or ROS mutant NSCLC or Non-smokers with lung metastasis
Expansion 2: Gastric cancer or solid tumour with biopsy available (consenting paired biopsies)refractory to standard therapies or for which no standard therapies exist. Patients with lymphoma & HCC are excluded.
For Part B : Advanced or metastatic HCC, unresectable and incurable with ablative therapy or TACE, with no standard therapy available.
Eastern Cooperative Oncology Group (ECOG) performance status 0-1 with no deterioration over the previous 2 weeks
For Part B : Child-Pugh liver function status classified as A to B7

Exclusion Criteria:

For any other chemotherapy, immunotherapy or anticancer agents, within 5 half lives or 3 weeks must have elapsed from treatment to of the first dose of investigational product, whichever is shorter.
With the exception of alopecia, any unresolved toxicities from prior therapy ≥ Grade 2 of CTCAE V4.02 at the time of starting study (except LFTs for HCC patients, which may be Grade 2 at the time of starting the study)
Any of the following conditions:Interferon treatment for HBV and HCV Prior Liver Transplantation
Inadequate bone marrow reserve or organ function as demonstrated by laboratory values
Evidence of established interstitial lung disease(ILD) on baseline high resolution computerized tomography(HRCT)